Literature DB >> 25380429

Anti-IL-5 biologics carve out severe-asthma niche.

Elie Dolgin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25380429     DOI： 10.1038/nbt1114-1075

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

Authors:  Elisabeth H Bel; Sally E Wenzel; Philip J Thompson; Charlene M Prazma; Oliver N Keene; Steven W Yancey; Hector G Ortega; Ian D Pavord
Journal:  N Engl J Med       Date:  2014-09-08       Impact factor: 91.245

2.  Mepolizumab treatment in patients with severe eosinophilic asthma.

Authors:  Hector G Ortega; Mark C Liu; Ian D Pavord; Guy G Brusselle; J Mark FitzGerald; Alfredo Chetta; Marc Humbert; Lynn E Katz; Oliver N Keene; Steven W Yancey; Pascal Chanez
Journal:  N Engl J Med       Date:  2014-09-08       Impact factor: 91.245
  2 in total
  2 in total

1.  Severe asthma gets first biologic in decades.

Authors:  Anna Azvolinsky
Journal:  Nat Biotechnol       Date:  2016-01       Impact factor: 54.908

Review 2.  Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma.

Authors:  Florence Roufosse
Journal:  Front Med (Lausanne)       Date:  2018-04-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.